Scarica l'app Stockscreener
6.115
1.24%
0.075
Dopo l'orario di chiusura:
6.15
0.035
+0.57%
Precedente Chiudi:
$6.04
Aprire:
$6.04
Volume 24 ore:
74,329
Relative Volume:
1.11
Capitalizzazione di mercato:
$175.28M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-8.73%
1M Prestazione:
-7.77%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.844
$6.15
Intervallo di 1 settimana:
$5.82
$6.66
Portata 52W:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Confronta IMDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.115 | 173.13M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Insight Molecular Diagnostics (IMDX) Price Target Increased by 29.23% to 7.14 - MSN
Will Insight Molecular Diagnostics Inc. (7OC0) stock remain on Wall Street radarJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock gain from green policiesQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Can Insight Molecular Diagnostics Inc. (7OC0) stock sustain institutional flowsJuly 2025 Breakouts & Verified High Yield Trade Plans - newser.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock stays resilient2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
Published on: 2025-11-19 17:04:49 - newser.com
Published on: 2025-11-19 13:52:26 - newser.com
Published on: 2025-11-19 13:17:14 - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock worth holding before Fed meetingMarket Volume Report & Capital Efficient Trade Techniques - newser.com
How Insight Molecular Diagnostics Inc. (7OC0) stock trades under stagflation2025 Sector Review & Precise Swing Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock a top pick for value investorsQuarterly Market Review & Free High Return Stock Watch Alerts - newser.com
This Biotech Stock Is Up 158% in a Year. What’s Driving It Higher? - MSN
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - Markets Financial Content
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study - MSN
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating (IMDX) - Seeking Alpha
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Non sono disponibili dati finanziari per Insight Molecular Diagnostics Inc (IMDX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):